Cyclin D1 expression predicts mismatch repair deficiency and correlates significantly with overall survival and recurrence free survival in endometrial carcinoma.

Aya Mohamed Saied, Samar Mohamed ElSheikh, Mohammed Elshazly, Marwa M Abd ElAziz

Abstract read

In one paragraph

Article in Journal of molecular histology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Aya Mohamed SaiedDepartment of Pathology, Faculty of Medicine, Alexandria University, El Azareeta Medical Campus, 3rd floor Academic Building, Champollion Street, El-Khartoum Square, Alexandria, 21131, Egypt.

Samar Mohamed ElSheikhDepartment of Pathology, Faculty of Medicine, Alexandria University, El Azareeta Medical Campus, 3rd floor Academic Building, Champollion Street, El-Khartoum Square, Alexandria, 21131, Egypt.

Mohammed ElshazlyDepartment of Clinical Oncology and Nuclear Medicine, Faculty of Medicine, Alexandria University, Alexandria, Egypt.

Marwa M Abd ElAzizDepartment of Pathology, Faculty of Medicine, Alexandria University, El Azareeta Medical Campus, 3rd floor Academic Building, Champollion Street, El-Khartoum Square, Alexandria, 21131, Egypt. Marwa.abdelaziz2009@alexmed.edu.eg.ORCID http://orcid.org/0000-0003-4230-7775

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Endometrial carcinoma is among the most common female malignancies. Many prognostic factors of endometrial carcinoma are proposed to predict survival in endometrial carcinoma patients. Cyclin D1 has been implicated in many malignancies including gastrointestinal and breast carcinoma. To correlate the immunohistochemical expression of Cyclin D1 in endometrial carcinoma with the different clinicopathological parameters. Forty-five cases of endometrial carcinoma with different histological subtypes and grades were included. Cyclin D1 expression was immunohistochemically tested. For each case, the predominant intensity was recorded, the density (as the percentage of positively stained cells irrespective of intensity) and H-score were recorded. Moreover, immunohistochemical staining for p53 and mismatch repair (MMR) proteins was done. All included cases showed different degrees of Cyclin D1 expression. Cyclin D1 expression was predominantly strong in 20 cases (44.4%). The density ranged from 1 to 90% and the H-score ranged from 1 to 270. Both H-score and density correlated significantly with MMR deficiency (p = 0.024 & p = 0.043 respectively) with different cut-offs (> 65 and > 20 respectively). Similarly, a predominant strong intensity correlated significantly with MMR deficiency (p = 0.023). Only Cyclin D1 density correlated significantly with FIGO grade (p = 0.036). At the assigned cut-off, H-score correlated significantly with the overall survival (p = 0.023). When predominantly moderately expressed, Cyclin D1 correlated significantly with recurrence free survival (p = 0.038). Cyclin D1 expression may predict MMR status and correlates with both overall survival and recurrence free survival in endometrial carcinoma.

Indexed as

Cyclin D1DNA Mismatch RepairEndometrial NeoplasmsAdultAgedAged, 80 and overBiomarkers, TumorDisease-Free SurvivalFemaleHumansImmunohistochemistryMiddle AgedPrognosisBiomarkers, TumorCCND1 protein, humanCyclin D1Cyclin D1Endometrial carcinomaMismatch repairOverall survivalRecurrence -free survival

Identifiers

PMID41219637

DOI10.1007/s10735-025-10636-8

What Socratic holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.